Phase I trial of SGN-35 shows efficacy against refractory lymphomas

hodgkins-histopathology.jpg

Results of a Phase 1 trial of Seattle Genetics' lead drug candidate brentuximab vedotin suggest that this hyped drug may warrant indications in patients with refractory lymphoma / relapsed lymphoma.

Read more about this news item at CancerTreatment.net.

LymphomaInfo Social